ATYR Stock Risk & Deep Value Analysis
aTyr Pharma Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About ATYR Stock
We analyzed aTyr Pharma Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ATYR through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is ATYR Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
Competitive Risk
Medium
Execution Risk
Medium
Regulatory Risk
High
What Are the Red Flags for ATYR?
- ⚠
Negative or inconclusive Phase 3 interim data
- ⚠
Failure to secure sufficient funding for Phase 3 completion
- ⚠
Significant delays in Phase 3 trial enrollment or timeline
- ⚠
Competitor advancement in dermatomyositis or related indications
Unlock ATYR Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does aTyr Pharma Inc (ATYR) Do?
Market Cap
$97.99M
Sector
Healthcare
Industry
Biotechnology
Employees
56
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; and in Phase 1b/2a clinical trial to treat other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Visit aTyr Pharma Inc WebsiteIs ATYR Stock Undervalued?
Unlock the full AI analysis for ATYR
Get the complete DVR score, risk analysis, and more
Does ATYR Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat, primarily derived from proprietary drug mechanism and regulatory exclusivity, is dependent on the successful completion of clinical trials and subsequent market approval. If successful, the ODD and patent protection would provide a strong, albeit time-limited, barrier to entry.
Moat Erosion Risks
- •Clinical trial failure (lack of efficacy or safety issues)
- •Patent challenges or expiry reducing market exclusivity
- •Emergence of superior or more cost-effective treatments from competitors
ATYR Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive ATYR Stock Higher?
Near-Term (0-6 months)
- •Q4 2025 Earnings Report (Estimated March 2026)
- •Updates on efzofitimod Phase 3 patient enrollment/timeline
Medium-Term (6-18 months)
- •Potential interim data readout from efzofitimod Phase 3 trial (Dermatomyositis)
- •Announcement of new strategic financing to extend runway (likely dilutive)
- •Expansion into additional rare disease indications for efzofitimod
Long-Term (18+ months)
- •Full Phase 3 data readout and successful primary endpoint achievement
- •Submission of Biologics License Application (BLA) for efzofitimod
- •Potential for partnership or acquisition following successful clinical milestones
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for ATYR?
- ✓
Positive Phase 3 clinical trial updates or interim data readouts for efzofitimod
- ✓
New non-dilutive financing or strategic partnership announcements
- ✓
Significant insider buying activity
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ATYR (aTyr Pharma Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
